Commission Implementing Regulation (EU) 2022/1480 of 7 September 2022 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 2-phenylphenol (including its salts such as the sodium salt), 8-hydroxyquinoline, amidosulfuron, bensulfuron, bifenox, chlormequat, chlorotoluron, clofentezine, clomazone, daminozide, deltamethrin, dicamba, difenoconazole, diflufenican, dimethachlor, esfenvalerate, etofenprox, fenoxaprop-P, fenpropidin, fenpyrazamine, fludioxonil, flufenacet, flumetralin, fosthiazate, lenacil, MCPA, MCPB, nicosulfuron, paraffin oils, paraffin oil, penconazole, picloram, prohexadione, propaquizafop, prosulfocarb, quizalofop-P-ethyl, quizalofop-P-tefuryl, sodium 5-nitroguaiacolate, sodium o-nitrophenolate, sodium p-nitrophenolate, sulphur, tebufenpyrad, tetraconazole, tri-allate, triflusulfuron and tritosulfuron (Text with EEA relevance)

• CELEX: Implementing Regulation (EU) 2022/1480
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(a)

Part A is amended as follows:

(1)

in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘31 October 2023’;

(2)

in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘31 October 2023’;

(3)

in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 October 2023’;

(4)

in the sixth column, expiration of approval, of row 102, Chlorotoluron, the date is replaced by ‘31 October 2023’;

(5)

in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘31 October 2023’;

(6)

in the sixth column, expiration of approval, of row 107, MCPA, the date is replaced by ‘31 October 2023’;

(7)

in the sixth column, expiration of approval, of row 108, MCPB, the date is replaced by ‘31 October 2023’;

(8)

in the sixth column, expiration of approval, of row 160, Prosulfocarb, the date is replaced by ‘31 October 2023’;

(9)

in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘31 October 2023’;

(10)

in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘31 October 2023’;

(11)

in the sixth column, expiration of approval, of row 169, Amidosulfuron, the date is replaced by ‘31 December 2023’;

(12)

in the sixth column, expiration of approval, of row 170, Nicosulfuron, the date is replaced by ‘31 December 2023’;

(13)

in the sixth column, expiration of approval, of row 171, Clofentezine, the date is replaced by ‘31 December 2023’;

(14)

in the sixth column, expiration of approval, of row 172, Dicamba, the date is replaced by ‘31 December 2023’;

(15)

in the sixth column, expiration of approval, of row 173, Difenoconazole, the date is replaced by ‘31 December 2023’;

(16)

in the sixth column, expiration of approval, of row 176, Lenacil, the date is replaced by ‘31 December 2023’;

(17)

in the sixth column, expiration of approval, of row 178, Picloram, the date is replaced by ‘31 December 2023’;

(18)

in the sixth column, expiration of approval, of row 180, Bifenox, the date is replaced by ‘31 December 2023’;

(19)

in the sixth column, expiration of approval, of row 181, Diflufenican, the date is replaced by ‘31 December 2023’;

(20)

in the sixth column, expiration of approval, of row 182, Fenoxaprop-P, the date is replaced by ‘31 December 2023’;

(21)

in the sixth column, expiration of approval, of row 183, Fenpropidin, the date is replaced by ‘31 December 2023’;

(22)

in the sixth column, expiration of approval, of row 186, Tritosulfuron, the date is replaced by ‘30 November 2023’;

(23)

in the sixth column, expiration of approval, of row 271, Bensulfuron, the date is replaced by ‘31 October 2023’;

(24)

in the sixth column, expiration of approval, of row 272, Sodium 5-nitroguaiacolate, the date is replaced by ‘31 October 2023’;

(25)

in the sixth column, expiration of approval, of row 273, Sodium o-nitrophenolate, the date is replaced by ‘31 October 2023’;

(26)

in the sixth column, expiration of approval, of row 274, Sodium p-nitrophenolate, the date is replaced by ‘31 October 2023’;

(27)

in the sixth column, expiration of approval, of row 275, Tebufenpyrad, the date is replaced by ‘31 October 2023’;

(28)

in the sixth column, expiration of approval, of row 276, Chlormequat, the date is replaced by ‘30 November 2023’;

(29)

in the sixth column, expiration of approval, of row 278, Propaquizafop, the date is replaced by ‘30 November 2023’;

(30)

in the sixth column, expiration of approval, of row 279, Quizalofop-P-ethyl and Quizalofop-P-tefuryl, the date is replaced by ‘30 November 2023’;

(31)

in the sixth column, expiration of approval, of row 284, Dimethachlor, the date is replaced by ‘31 December 2023’;

(32)

in the sixth column, expiration of approval, of row 285, Etofenprox, the date is replaced by ‘31 December 2023’;

(33)

in the sixth column, expiration of approval, of row 287, Penconazole, the date is replaced by ‘31 December 2023’;

(34)

in the sixth column, expiration of approval, of row 288, Tri-allate, the date is replaced by ‘31 December 2023’;

(35)

in the sixth column, expiration of approval, of row 289, Triflusulfuron, the date is replaced by ‘31 December 2023’;

(36)

in the sixth column, expiration of approval, of row 292, Sulphur, the date is replaced by ‘31 December 2023’;

(37)

in the sixth column, expiration of approval, of row 293, Tetraconazole, the date is replaced by ‘31 December 2023’;

(38)

in the sixth column, expiration of approval, of row 294, Paraffin oils, the date is replaced by ‘31 December 2023’;

(39)

in the sixth column, expiration of approval, of row 295, Paraffin oil, the date is replaced by ‘31 December 2023’;

(40)

in the sixth column, expiration of approval, of row 299, 2-phenylphenol (including its salts such as the sodium salt), the date is replaced by ‘31 December 2023’;

(b)

Part B is amended as follows:

(1)

in the sixth column, expiration of approval, of row 6, Prohexadione, the date is replaced by ‘31 December 2023’;

(2)

in the sixth column, expiration of approval, of row 18, 8-hydroxyquinoline, the date is replaced by ‘31 December 2023’;

(3)

in the sixth column, expiration of approval, of row 25, Fenpyrazamine, the date is replaced by ‘31 December 2023’;

(c)

Part E is amended as follows:

(1)

in the sixth column, expiration of approval, of row 1, Flumetralin, the date is replaced by ‘11 December 2023’;

(2)

in the sixth column, expiration of approval, of row 2, Esfenvalerate, the date is replaced by ‘31 December 2023’.